XENETIC BIOSCIENCES
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-08-01
- Employees
- 4
- Market Cap
- $6.3M
- Website
- http://www.xeneticbio.com
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
Phase 2
Terminated
- Conditions
- Endometrial Cancer
- Interventions
- Drug: progestin therapy
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- Xenetic Biosciences, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT03077698
- Locations
- 🇺🇸
Saint Alphonsus Regional Medical Center, Boise, Idaho, United States
🇺🇸UT Southwestern, Dallas, Texas, United States
🇺🇸University of California - Irvine Healthcare, Irvine, California, United States
© Copyright 2025. All Rights Reserved by MedPath